AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Levi & Korsinsky Announces an Investigation on Behalf of AstraZeneca PLC (AZN) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
AZN STOCK ALERT: Levi & Korsinsky Notifies AstraZeneca PLC Investors of an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
AstraZeneca's Imfinzi Gets FDA Nod for Expanded Use in SCLC
The FDA approves AZN's Imfinzi for treating patients with limited-stage small-cell lung cancer based on phase III ADRIATIC study data.
Here's Why Astrazeneca (AZN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
AstraZeneca PLC (AZN) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
NEW YORK, NY / ACCESSWIRE / December 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
US regulator approves AstraZeneca's Imfinzi for small cell lung cancer
AstraZeneca PLC's (LSE:AZN) Imfinzi (durvalumab) has received approval from the U.S. Food and Drug Administration (FDA) as the first immunotherapy treatment for limited-stage small cell lung cancer (LS-SCLC).
FDA approves AstraZeneca's Imfinzi for limited-stage small cell lung cancer
The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with limited-stage small cell lung cancer, the health regulator said on Wednesday.
AstraZeneca names new international Executive VP to succeed Leon Wang
AstraZeneca said on Wednesday Iskra Reic will become its new international executive vice president succeeding Leon Wang, who was detained by Chinese authorities in October.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by AstraZeneca PLC (AZN)
NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
Novo Nordisk and AstraZeneca top of the 2025 drug picks for US investment bank - read why
Success in 2025 for the pharma sector will hinge on the success of key drug pipeline developments, according to JPMorgan's latest research. With concerns over US drug pricing policies easing and significant patent expirations on the horizon, the focus shifts to pipeline progress to drive growth, the American investment bank reckons, And it says Novo Nordisk (NYSE:NVO) and AstraZeneca PLC (LSE:AZN) are set to lead the way, bolstered by strong mid-term growth and promising news flow.
AZN ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by AstraZeneca PLC
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible violations of federal securities laws. On November 5, 2024, the Chinese news outlet Yicai reported that a fraud investigation into AstraZeneca has expanded to include several agencies of the Chinese government, implicating dozens of senior executives at the Company.
AstraZeneca's Enhertu included in China's state insurance reimbursement
AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an update from the National Healthcare Security Administration.
